Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals focuses on developing treatments for cardiometabolic, pulmonary, liver, and neuromuscular diseases using its TRiM™ platform for targeted RNAi molecule delivery. The company aims to have 20 products in clinical trials or on the market by 2025, with several candidates currently in various trial phases.
Company Overview
Arrowhead Pharmaceuticals focuses on developing treatments for cardiometabolic, pulmonary, liver, and neuromuscular diseases. Utilizing RNAi technology, the company targets genes causing these diseases. Their research and development facilities are located in Madison, WI, and San Diego, CA, with corporate headquarters in Pasadena, CA.
Pipeline and Clinical Trials
Arrowhead Pharmaceuticals has an extensive pipeline with multiple products in various stages of clinical trials. Notable examples include ARO-APOC3 (Plozasiran) in Phase 3 trials for severe hypertriglyceridemia, ARO-RAGE in Phase 1 trials for inflammatory pulmonary diseases, and Olpasiran, licensed to Amgen, in Phase 3 trials for cardiovascular disease. Additionally, ARO-DUX4 and ARO-DM1 are in Phase 1/2a trials for facioscapulohumeral muscular dystrophy type 1 and myotonic dystrophy type 1, respectively.
TRiM™ Platform
The TRiM™ platform is Arrowhead Pharmaceuticals’ proprietary technology used for the targeted delivery of RNA interference (RNAi) molecules. This platform is instrumental in the development of their treatments, enabling precision targeting of specific genes involved in disease processes.
Collaborations and Licensing
Arrowhead Pharmaceuticals engages in collaboration and licensing agreements with leading biotechnology and pharmaceutical companies. These partnerships are essential for expanding their research and bringing innovative treatments to market. Notable collaborations include licensing Olpasiran to Amgen for cardiovascular disease.
Future Goals
Arrowhead Pharmaceuticals has set a goal to have 20 individual products in clinical trials or on the market by 2025. This ambitious target underscores the company’s commitment to advancing its pipeline and delivering new therapies for a range of diseases.